Linatera

Drospirenone/Ethinylestradiol, the active ingredient in Linatera, is a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy and helps regulate menstrual cycles in women of reproductive age.

GNH USA supplies Linatera as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, offering EU‑approved quality, batch‑tested products and reliable logistics for global distribution. Our supply chain adheres to stringent regulatory requirements, ensuring product integrity from manufacturing to delivery.

Linatera is a combined hormonal contraceptive that acts on the reproductive endocrine system to prevent unintended pregnancy and manage menstrual function. - Prevention of pregnancy: provides reliable contraception for women of child‑bearing age. - Regulation of menstrual cycles: helps achieve more predictable cycle length and flow. - Management of menstrual‑related symptoms: reduces dysmenorrhea and premenstrual discomfort.

Linatera may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: temporary swelling or discomfort. - Headache: occasional tension‑type headaches. - Spotting or breakthrough bleeding: irregular light bleeding. - Weight gain: modest increase in body weight. - Mood changes: irritability or mild mood swings.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Arterial thrombosis: stroke or myocardial infarction. - Hypertension: new‑onset high blood pressure. - Liver disorders: cholestatic jaundice or hepatic dysfunction. - Gallbladder disease: gallstones or cholecystitis. - Severe allergic reactions: anaphylaxis or angioedema.

Before prescribing Linatera, clinicians should consider several safety factors. - Contraindications: avoid in women with known thromboembolic disorders or hormone‑dependent cancers. - Smoking: contraindicated in women over 35 who smoke due to increased cardiovascular risk. - History of thrombosis: assess risk and consider alternative contraception. - Liver disease: use with caution in patients with active liver disease. - Pregnancy: discontinue immediately if pregnancy is confirmed; not intended for use during pregnancy. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Linatera can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): markedly reduce contraceptive effectiveness. - Rifampin or other potent inducers: may lead to contraceptive failure. - Certain antiretroviral protease inhibitors: unpredictable effects on hormone levels.

Moderate Interactions (Monitor Closely): - St. John’s wort: may decrease plasma concentrations, reducing efficacy. - Antifungal azoles (e.g., ketoconazole): can increase hormone levels, raising side‑effect risk. - Macrolide antibiotics (e.g., erythromycin): may modestly affect hepatic metabolism and hepatic enzyme activity.